A/Prof Su Xinyi

Affiliations

Executive Director, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research

Research Director, Stem Cell and Therapies for Retinal Diseases Lab (IMCB)

Senior Consultant, Vitreo-retinal Surgeon, National University Hospital (NUH)

Assoc Prof & Co-Director, Centre of Innovation and Precision Eye Health (NUS)

Profile

A/Prof Su Xinyi took on the role as Executive Director at IMCB with effect from 1 March 2024, stepping up from her previous roles as Acting Executive Director and Deputy Executive Director (Strategy and Transformation) at IMCB.    

A/Prof Su, an A*STAR scholar, graduated with MB BChir PhD from the University of Cambridge (UK) and joined IMCB in 2016 as a clinician-scientist. She balances her time leading a broad retinal research program as Research Director at IMCB, while providing clinical leadership as Senior Consultant, Vitreo-Retinal Surgeon at the National University Hospital. A/Prof Su also holds joint appointments as Research Director at the Department of Ophthalmology (NUS), Co-Director at the Centre of Innovation and Precision Eye Health (NUS), and Clinician-Scientist at the Singapore Eye Research Institute (SERI). 

Her research interests focus on harnessing biomaterial, regenerative stem-cell, and nucleic acid technologies for the treatment of age-related retinal degenerative disease. Her research has been published in, inter alia, Nature Biomedical Engineering, Nature Communications, Lancet Global Health, PNAS, and Advanced Materials. She is a recipient of multiple global and national awards, including the Asia-Pacific Academy of Ophthalmology’s Young Ophthalmologist Award (2019), the Asia-Pacific Vitreo-Retinal Society Leadership Development Program Gold Award (2020), Singapore Ten Outstanding Young Persons of Singapore Award (for Medical Innovation, 2021), Susan Lim Outstanding Stem Cell Young Investigator Award (2022) and National Medical Research Council Clinician Scientist Award (2022). In 2022, she was accepted into the prestigious international membership of The Macular Society.    

Passionate about clinical translation of research, A/Prof Su holds several patents and co-founded an ISO 13485 (Medical Device Quality System) accredited spin-off company, Vitreogel Innovations, focussed on developing the next generation of vitreous substitutes. Beyond research, A/Prof Su is committed to people development and has mentored numerous clinician-scientists as the Deputy Director of the Clinician-Scientist Academy at NUHS.